ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
-4.52%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$206M
AUM Growth
+$206M
(-41%)
Cap. Flow
-$76.7M
Cap. Flow
% of AUM
-37.17%
Top 10 Holdings %
Top 10 Hldgs %
61.73%
Holding
45
New
9
Increased
7
Reduced
14
Closed
12
Top Buys
| 1 |
Verastem
VSTM
|
$9.5M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$8.22M |
| 3 |
BioXcel Therapeutics
BTAI
|
$7.04M |
| 4 |
Gyre Therapeutics
GYRE
|
$6.05M |
| 5 |
LSACU
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
|
$5.6M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$20.1M |
| 2 |
Axsome Therapeutics
AXSM
|
$17.6M |
| 3 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$15.4M |
| 4 |
Karyopharm Therapeutics
KPTI
|
$11.3M |
| 5 |
Arrowhead Research
ARWR
|
$9.57M |
Sector Composition
| 1 | Healthcare | 93.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVDL
1
Avadel Pharmaceuticals
AVDL
$1.43B
| $20.9M | 10.15% | 2,673,718 +1,048,718 | +65% | +$8.22M |
|
|
2
Axsome Therapeutics
AXSM
$6.05B
| $18.1M | 8.8% | 308,500 -299,000 | -49% | -$17.6M |
|
3
Adverum Biotechnologies
ADVM
$64.6M
| $16.7M | 8.07% | 1,704,500 +382,000 | +29% | +$3.73M |
|
4
Iovance Biotherapeutics
IOVA
$807M
| $12M | 5.8% | 399,500 -257,000 | -39% | -$7.69M |
|
5
Arvinas
ARVN
$568M
| $11.3M | 5.47% | 280,120 -75,880 | -21% | -$3.06M |
|
6
Aurinia Pharmaceuticals
AUPH
$1.58B
| $11.2M | 5.42% | 770,000 -287,500 | -27% | -$4.17M |
|
|
BLU
7
DELISTED
BELLUS Health Inc.
BLU
| $10.7M | 5.18% | 1,070,000 +260,000 | +32% | +$2.59M |
|
|
KDMN
8
DELISTED
Kadmon Holdings, Inc.
KDMN
| $9.89M | 4.79% | 2,360,000 -3,680,000 | -61% | -$15.4M |
|
|
9
Verastem
VSTM
$569M
| $9.5M | 4.6% | +3,720,930 | New | +$9.5M |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $7.13M | 3.45% | 628,500 -289,000 | -31% | -$3.28M |
|
11
Ascendis Pharma
ASND
$11.8B
| $7.12M | 3.45% | 63,200 +40,700 | +181% | +$4.58M |
|
|
12
BioXcel Therapeutics
BTAI
$59M
| $7.04M | 3.41% | +315,000 | New | +$7.04M |
|
|
13
Gyre Therapeutics
GYRE
$703M
| $6.05M | 2.93% | +1,384,600 | New | +$6.05M |
|
14
Cartesian Therapeutics
RNAC
$261M
| $5.7M | 2.76% | 2,364,204 | – | – |
|
15
Apellis Pharmaceuticals
APLS
$3.48B
| $5.61M | 2.72% | 209,500 +22,000 | +12% | +$589K |
|
|
LSACU
16
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
| $5.6M | 2.71% | +560,000 | New | +$5.6M |
|
17
Mersana Therapeutics
MRSN
$36.5M
| $4.82M | 2.34% | +827,500 | New | +$4.82M |
|
|
DRNA
18
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $4.71M | 2.28% | 256,500 -131,000 | -34% | -$2.41M |
|
|
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $4.38M | 2.12% | 139,464 -58,036 | -29% | -$1.82M |
|
|
KRTX
20
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $4.03M | 1.95% | 56,000 | – | – |
|
|
RETA
21
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.39M | 1.64% | 23,500 -14,500 | -38% | -$2.09M |
|
22
Applied Therapeutics
APLT
$71M
| $3.33M | 1.62% | 102,000 -46,000 | -31% | -$1.5M |
|
|
23
Arrowhead Research
ARWR
$3.05B
| $3.16M | 1.53% | 109,700 -332,800 | -75% | -$9.57M |
|
24
Relmada Therapeutics
RLMD
$37.2M
| $3.1M | 1.5% | +90,950 | New | +$3.1M |
|
25
uniQure
QURE
$896M
| $2.52M | 1.22% | 53,000 +28,000 | +112% | +$1.33M |
|